Gregory J Riely

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 13:5150-5. 2007
  2. ncbi request reprint A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1435-7. 2011
  3. ncbi request reprint Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Thorac Oncol 3:S146-9. 2008
  4. pmc Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10022, USA
    J Clin Oncol 27:264-70. 2009
  5. pmc Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 14:5731-4. 2008
  6. doi request reprint Induction therapy for locally advanced thymoma
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Thorac Oncol 5:S323-6. 2010
  7. pmc Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:2240-7. 2013
  8. doi request reprint Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
    Sandra P D'Angelo
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:1815-22. 2012
  9. pmc Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Mol Cancer Ther 11:485-91. 2012
  10. ncbi request reprint Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer
    Daniel T Milton
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York, USA
    Cancer 110:599-605. 2007

Detail Information

Publications72

  1. ncbi request reprint Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 13:5150-5. 2007
    ..In these patients, we sought to assess changes in tumor metabolism and size after stopping and restarting erlotinib or gefitinib and to determine the effect of adding everolimus...
  2. ncbi request reprint A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1435-7. 2011
    ..Salirasib prevents Ras membrane binding thereby blocking the function of all Ras isoforms. This phase II study determined the activity of salirasib in patients with advanced lung adenocarcinomas with KRAS mutations...
  3. ncbi request reprint Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Thorac Oncol 3:S146-9. 2008
    ..The preliminary results from phase I and phase II trials for BIBW-2992 and XL647 are discussed...
  4. pmc Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10022, USA
    J Clin Oncol 27:264-70. 2009
    ..However, preclinical data support the hypothesis that intermittent administration of erlotinib before or after chemotherapy may improve efficacy. We tested this hypothesis in patients with advanced NSCLC...
  5. pmc Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 14:5731-4. 2008
    ..These mutations are predictive of poor prognosis in resected disease as well as resistance to treatment with erlotinib or gefitinib...
  6. doi request reprint Induction therapy for locally advanced thymoma
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Thorac Oncol 5:S323-6. 2010
    ..In this review, we summarize the published experience with preoperative therapy for thymoma and discuss ongoing clinical trials exploring multimodality therapy for treatment of locally advanced thymoma...
  7. pmc Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:2240-7. 2013
    ..Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large number of patients to definitively establish the frequency of various mechanisms has not been conducted...
  8. doi request reprint Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
    Sandra P D'Angelo
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:1815-22. 2012
    ..The clinical significance of these mutations in patients with resected stage I-III lung cancers is unclear...
  9. pmc Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Mol Cancer Ther 11:485-91. 2012
    ..Given the high frequency of overlapping mutations, comprehensive genotyping should be carried out on tumor specimens from patients enrolling in clinical trials of PI3K and other targeted therapies...
  10. ncbi request reprint Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer
    Daniel T Milton
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York, USA
    Cancer 110:599-605. 2007
    ..A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dose of everolimus with gefitinib in patients with advanced nonsmall-cell lung cancer (NSCLC)...
  11. pmc Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer
    Katharine A Price
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York City, New York, USA
    J Thorac Oncol 5:1623-9. 2010
    ..This phase II trial assessed the efficacy of the combination of gefitinib and everolimus in patients with advanced NSCLC...
  12. pmc A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion
    Paul K Paik
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, H1011, New York, NY 10065, USA
    Cancer Chemother Pharmacol 68:1331-7. 2011
    ..We sought to determine if the incidence and severity of peripheral neuropathy could be reduced when the infusion time is lengthened to 2-h...
  13. ncbi request reprint Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
    Marissa N Balak
    Human Oncology and Pathogenesis Program, Thoracic Oncology Service, Varmus Lab, Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 12:6494-501. 2006
    ..We aimed to elucidate the frequency and nature of secondary EGFR mutations in patients with acquired resistance to TKI monotherapy...
  14. pmc Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers
    Snjezana Dogan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6169-77. 2012
    ..The molecular epidemiology of most EGFR and KRAS mutations in lung cancer remains unclear...
  15. pmc Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas
    Paul K Paik
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:5840-7. 2012
    ..In this study, the authors hypothesized that smoking-dependent differences in the distribution of driver mutations may explain differences in prognosis between these subgroups...
  16. ncbi request reprint Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 12:839-44. 2006
    ..We undertook this study to explore the relationship between EGFR mutation type and clinical variables, including treatment with gefitinib and erlotinib...
  17. pmc Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
    Clin Cancer Res 17:1616-22. 2011
    ..In half of these cases, a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of patients harboring the T790M mutation following progression on TKI...
  18. pmc EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression
    Allan R Li
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Mol Diagn 10:242-8. 2008
    ..Thus, these results indicate that EGFR amplification, preferentially of the mutant allele, often accompanies EGFR mutation, whereas EGFR immunohistochemical staining associates with amplification but cannot predict EGFR mutation status...
  19. ncbi request reprint Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas
    DuyKhanh Pham
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:1700-4. 2006
    ..Investigators have reported an association between EGFR mutations and the amount and duration of cigarette smoking, with the highest incidence of mutations seen in never smokers...
  20. doi request reprint Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
    Vincent A Miller
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1472-8. 2008
    ..We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response...
  21. ncbi request reprint Insulin-like growth factor-1 receptor expression in thymic malignancies
    Nicolas Girard
    Human Oncology and Pathogenesis Program, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
    J Thorac Oncol 5:1439-46. 2010
    ..As higher levels of IGF-1R protein expression may be associated with relative sensitivity to anti-IGF-1R antibody treatment, we investigated IGF-1R expression in thymic malignancies...
  22. doi request reprint Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
    Yelena Y Janjigian
    Gastrointestinal and Thoracic Oncology Services, Division of Solid Tumor Oncology, Department of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
    Clin Cancer Res 17:2521-7. 2011
    ..To evaluate the toxicity and efficacy of cetuximab and erlotinib in patients with acquired resistance to erlotinib, we conducted this phase I/II clinical trial...
  23. pmc Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas
    Sandra P D'Angelo
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
    J Clin Oncol 29:2066-70. 2011
    ..EGFR mutations underlie the sensitivity of lung cancers to erlotinib and gefitinib and can occur in any patient with this illness. Here we examine the frequency of EGFR mutations in smokers and men...
  24. pmc Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma
    James Bean
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 14:7519-25. 2008
    ..We aimed to identify additional second-site alterations associated with acquired resistance...
  25. ncbi request reprint Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma
    Naamit K Gerber
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
    Int J Radiat Oncol Biol Phys 89:322-9. 2014
    ..However, given the activity of EGFR tyrosine kinase inhibitors in the central nervous system, it is uncertain whether upfront brain RT is necessary for patients with EGFR-mutant lung adenocarcinoma with BM...
  26. doi request reprint Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
    Matthew D Hellmann
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School, 300 East 66th Street, New York, NY 10065, USA
    Cancer Chemother Pharmacol 72:453-61. 2013
    ..The risk of hemoptysis may be eliminated in patients with resected SQCLCs. We evaluated the safety of adjuvant bevacizumab in patients with resected SQCLCs and other lung cancers at high risk of hemoptysis...
  27. pmc Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers
    Anna M Varghese
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 8:123-5. 2013
    ....
  28. pmc Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA
    J Thorac Oncol 8:346-51. 2013
    ..Metastasectomy is used in other cancers to manage oligometastatic disease. We hypothesized that local therapy is associated with improved outcomes in patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKI...
  29. pmc Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 17:6322-8. 2011
    ..To better understand these results, we studied the natural history of lung cancers which recurred despite adjuvant TKI...
  30. ncbi request reprint Molecular on/off switch
    Daniel T Milton
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weil Medical College of Cornell University, New York, NY, USA
    J Clin Oncol 24:4940-2. 2006
  31. pmc Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease
    Kyuichi Kadota
    Department of Surgery, Division of Thoracic Service Department of Pathology Department of Epidemiology and Biostatistics Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University, Kagawa Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto Department of Diagnostic Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
    Am J Surg Pathol 38:448-60. 2014
    ..5 cm; n=2), 20% to 30% micropapillary component (n=2), and lymphatic or vascular invasion (n=2). It therefore may be possible to identify lepidic predominant adenocarcinomas that carry a low or high risk for recurrence. ..
  32. pmc Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes
    Geoffrey R Oxnard
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 29:3114-9. 2011
    ..In this study, we assess the variability of lung tumor measurement using repeat CT scans performed within 15 minutes of each other and discuss the implications of this variability in a clinical context...
  33. pmc Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans
    J Matthew Reinersman
    Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:28-31. 2011
    ..KRAS mutations confer resistance to EGFR-tyrosine kinase inhibitors. The prevalence of these mutations in African American patients has not been thoroughly investigated...
  34. pmc Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    William Pao
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Med 2:e73. 2005
    ..Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance...
  35. doi request reprint Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer
    M Catherine Pietanza
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA
    J Thorac Oncol 7:856-65. 2012
    ..We undertook an open-label, multi-institutional Phase II study to investigate the efficacy and safety of XL647 in treatment-naive non-small-cell lung cancer patients clinically enriched for the presence of EGFR mutations...
  36. pmc Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
    Maria E Arcila
    Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 17:1169-80. 2011
    ..Here, we sought to determine the feasibility of tumor rebiopsy and to more accurately assess the prevalence of the T790M using a highly sensitive locked nucleic acid (LNA) PCR/sequencing assay. MET amplification was also analyzed...
  37. doi request reprint Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases
    Akihiko Yoshizawa
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Mod Pathol 24:653-64. 2011
    ..The slightly stronger association with survival for invasive size versus gross size raises the need for further studies to determine whether this adjustment in measuring tumor size could impact TNM staging for small adenocarcinomas...
  38. ncbi request reprint KRAS mutational testing in the selection of patients for EGFR-targeted therapies
    Joaquin Garcia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Semin Diagn Pathol 25:288-94. 2008
    ....
  39. pmc Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers
    Jamie E Chaft
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    J Thorac Oncol 8:1084-90. 2013
    ..Bevacizumab improves survival in patients with advanced non-small-cell lung cancer (NSCLC). This phase II clinical trial assessed the effects of the addition of bevacizumab to neoadjuvant chemotherapy in resectable nonsquamous NSCLC...
  40. pmc Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:6298-303. 2011
    ..To examine this observation and define the course of patients following TKI discontinuation, we systematically evaluated patients enrolled on clinical trials of agents to treat acquired resistance to erlotinib or gefitinib...
  41. doi request reprint Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens
    Carlie S Sigel
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:1849-56. 2011
    ..The relative feasibility and accuracy of NSCLC subtyping by small biopsy versus cytology is not well established, particularly in current practice where immunohistochemistry (IHC) is becoming routinely used to aid in this distinction...
  42. ncbi request reprint Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer
    Naiyer A Rizvi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:639-43. 2008
    ..We undertook this trial to determine the maximum-tolerated dose (MTD) and single-agent activity of NAB-paclitaxel administered on a weekly basis to patients with stage IV non-small-cell lung cancer (NSCLC)...
  43. ncbi request reprint A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lung Cancer 55:181-5. 2007
    ..TZT-1027, a derivative of dolastatin-10, has a wide spectrum of in vitro activity against cancer cell lines. We conducted a phase 2 trial of TZT-1027 in patients with previously treated non-small cell lung cancer (NSCLC)...
  44. pmc KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    William Pao
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Med 2:e17. 2005
    ..Lung adenocarcinomas also harbor activating mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be mutually exclusive...
  45. pmc KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 26:1307-19. 2013
    ..Solid growth pattern was recently shown to be a strong predictor of aggressive behavior in lung adenocarcinomas, which may underlie the unfavorable prognosis associated with KRAS mutations in these tumors. ..
  46. pmc Small-cell lung cancers in patients who never smoked cigarettes
    Anna M Varghese
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College Department of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
    J Thorac Oncol 9:892-6. 2014
    ..We describe clinical, pathologic, and molecular characteristics of never-smoker patients with small-cell lung cancers (SCLCs)...
  47. doi request reprint A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma
    Kyuichi Kadota
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 25:1117-27. 2012
    ..005) after adjusting for clinical factors. We proposed this combined architectural/mitotic grade for lung adenocarcinoma as a practical method that can be applied in routine practice...
  48. pmc Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations
    Paul K Paik
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
    J Clin Oncol 29:2046-51. 2011
    ..Therapies targeting BRAF mutant tumors have recently been identified. We undertook this study to determine the clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations...
  49. doi request reprint Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:451-8. 2011
    ..The aim of this study was to comprehensively review the performance of cytologic specimens for the above two goals in a high-volume clinical practice...
  50. pmc Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer
    Yelena Y Janjigian
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 116:670-5. 2010
    ....
  51. doi request reprint KRAS mutations in non-small cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Am Thorac Soc 6:201-5. 2009
    ..In this review, we summarize the initial discovery of RAS mutations in NSCLC, describe work exploring associations with clinical factors and outcomes, and provide an overview of current approaches to targeting KRAS mutant NSCLC...
  52. ncbi request reprint Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma: Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation
    Kyuichi Kadota
    Department of Surgery, Division of Thoracic Service Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology Departments of Pathology Epidemiology and Biostatistics Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY Faculty of Medicine, Department of Diagnostic Pathology, Kagawa University, Kagawa, Japan
    Am J Surg Pathol 38:1118-27. 2014
    ..001) but not with extracellular mucin (P=0.089). Our study shows that histologic patterns of mucin in lung adenocarcinoma-including invasive mucinous adenocarcinoma and extracellular mucin-are associated with KRAS mutation. ..
  53. pmc ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 19:4273-81. 2013
    ..Recently, several case reports and small series have reported that ALK rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naïve and crizotinib-resistant cancers...
  54. doi request reprint New pathologic classification of lung cancer: relevance for clinical practice and clinical trials
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 31:992-1001. 2013
    ....
  55. doi request reprint Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker
    M Catherine Pietanza
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Clin Cancer Res 18:1138-45. 2012
    ..This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer (SCLC)...
  56. pmc Comparison of patterns of relapse in thymic carcinoma and thymoma
    James Huang
    Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Thorac Cardiovasc Surg 138:26-31. 2009
    ..We reviewed our recent experience with the surgical management of thymic tumors and compared the outcomes and patterns of relapse between patients with thymic carcinoma and those with thymoma...
  57. ncbi request reprint Update on epidermal growth factor receptor mutations in non-small cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 12:7232-41. 2006
    ..Although a tremendous amount of knowledge has been gained in the past 2 years, there remain a number of important epidemiologic, biological, and clinical questions...
  58. pmc Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas
    Nicolas Girard
    Human Oncology and Pathogenesis Program HOPP, Weill Medical College of Cornell University, New York, New York, USA
    Clin Cancer Res 15:6790-9. 2009
    ..However, whether the underlying biology of these tumors warrants such clustering is unclear, and the optimum treatment of either entity is unknown...
  59. pmc Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
    Kadoaki Ohashi
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Proc Natl Acad Sci U S A 109:E2127-33. 2012
    ....
  60. ncbi request reprint The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations
    Gregory J Riely
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lung Cancer 60:S19-22. 2008
    ..Improved understanding of the association of EGFR mutations with clinical outcome may improve the ability of physicians to match treatment to mutation status for patients with NSCLC...
  61. pmc Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer
    Binsheng Zhao
    Departments of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 252:263-72. 2009
    ..To evaluate the variability of tumor unidimensional, bidimensional, and volumetric measurements on same-day repeat computed tomographic (CT) scans in patients with non-small cell lung cancer...
  62. ncbi request reprint Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis
    Noriko Motoi
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 32:810-27. 2008
    ..Such an approach should be considered in future studies for validation in other datasets...
  63. ncbi request reprint Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?
    Gregory J Riely
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Biol Ther 4:1096-7. 2005
  64. doi request reprint Management and outcomes of relapse after treatment for thymoma and thymic carcinoma
    Matthew J Bott
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Ann Thorac Surg 92:1984-91; discussion 1991-2. 2011
    ..Although surgery is the mainstay of treatment for thymic tumors, recurrence is common despite resection. The optimal approach to the management of disease relapse after treatment for thymic tumors remains unclear...
  65. pmc Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Natl Compr Canc Netw 11:161-9. 2013
    ....
  66. ncbi request reprint Vascular endothelial growth factor trap in non small cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College of Cornell University, New York, New York 10022, USA
    Clin Cancer Res 13:s4623-7. 2007
    ..Ongoing phase I trials are evaluating combinations of VEGF Trap with platinum-based doublets and single-agent docetaxel. The activity of single-agent VEGF Trap in NSCLC is being assessed in a multicenter phase II trial...
  67. doi request reprint International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Thorac Oncol 6:244-85. 2011
    ....
  68. pmc KRAS mutations: an old oncogene becomes a new predictive biomarker
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, New York, New York, USA
    J Mol Diagn 10:493-5. 2008
    ..This commentary highlights a novel assay for detection of mutations in KRAS, which have recently emerged as a useful negative predictive biomarker...
  69. doi request reprint EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations
    Jenifer L Marks
    J Thorac Oncol 3:805. 2008
  70. ncbi request reprint Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy
    Thomas J Lynch
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 3:S107-12. 2008
    ..A CME activity based on this summary is also available at www.informedicalcme.com/cme...
  71. ncbi request reprint Multimodality therapy for locally advanced thymomas: state of the art or investigational therapy?
    James Huang
    Ann Thorac Surg 85:365-7. 2008
  72. ncbi request reprint Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey, 7th Floor, Suite 7601, Boston, MA 02114, USA
    Clin Cancer Res 13:s4583-8. 2007
    ....